states and is particularly useful as a screening test in the antenatal diagnosis of fetal neural tube defects, which may be indicated by high concentrations of AFP in maternal serum (1, 2). Further, AFP is a valuable tumor marker and is useful both diagnostically and in the management of patients with hepatoma or with teratoma of the testis or ovary (3, 4). Radioimmunoassay is widely used for measuring circulating polypeptides, but it is generally accepted that immunoradiometric assays offer advantages in terms of rapidity, sensitivity, and specificity. These advantages have been exploited in the development of an automated two-site assay for AFP (5), which is particularly suited to high-throughput screening.
with increased specific activity. a1-Fetoprotein concentrations in the sera of pregnant women at 14-20 weeks of gestation, as measured by the present assay, agreed with the resultsof a conventionalradioimmunoassay.
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Measurement of serum a1-fetoprotein (AFP) is important in the diagnosis of several pathological
states and is particularly useful as a screening test in the antenatal diagnosis of fetal neural tube defects, which may be indicated by high concentrations of AFP in maternal serum (1, 2). Further, AFP is a valuable tumor marker and is useful both diagnostically and in the management of patients with hepatoma or with teratoma of the testis or ovary (3, 4). Radioimmunoassay is widely used for measuring circulating polypeptides, but it is generally accepted that immunoradiometric assays offer advantages in terms of rapidity, sensitivity, and specificity. These advantages have been exploited in the development of an automated two-site assay for AFP (5), which is particularly suited to high-throughput screening.
Further, Weeks et al. (6) recently demonstrated
the advantages of monoclonal antibodies in the development of a twosite immunoradiometric assay for AFP. In spite of their advantages, labeled antibody systems are still subject to the major constraint imposed by the use of as a label: reagent instability. Most non-isotopic labels, though considerably more stable than 'I, have failed to yield assays of equivalent sensitivity and are thus of little use for measuring low concentrations of circulating polypeptides. The preparation of chemiluminescent acridimum ester-labeled antibodies and their use in immunochemiluminometric assays (ICMA) has been described previously (7), and the advantages over their 'I-labeled counterparts have been discussed.
Here we describe the development of an assay based on this methodology and its application to measurement of AFP in maternal serum. 
Materials
Antibodies.
Monoclonal antibodies to AFP were generously donated by Hybritech Inc., La Jolla, CA 92037. Labeled antibodies were prepared by use of 4-(2-succinimidyloxycarbonylethyl)phenyl-10-methylacridinium-9-carboxylate fluorosulfonate as described previously (7). Rabbit (anti-AFP) IgG was obtained from Dakopatts through Mercia Brocades Ltd., Weybridge, Surrey, U.K. Sheep (anti-AFP) IgG immunoadsorbent was prepared from reprecipitated aminoaryl cellulose as described previously (5).
Standards.
A reference preparation of AFP (Code 72/227, 98500 kilo-mt. units/L) was obtained from the National 
Procedures
Optimization of antibody concentrations in the Icrvt. We prepared dose-response curves, using various amounts of solid-phase and labeled antibodies, to determine the concentrations that yielded the widest dynamic range and sensitivity for measuring AFP in the concentration range 1.9-246 kilo-mt. unitsfL. These conditions were then used in the routine assay.
Routine ic,uprotocol.
Labeled antibodies and solid-phase antibodies were diluted in assay buffer such that 100 /.LL contained 33 ng and 100 pg, respectively. Assay standards consisted of serial twofold dilutions of this standard in the diluent buffer. One-hundred-microliter aliquots of each standard were dispensed into assay tubes in triplicate, followed by 100 1zL of horse serum. Patients' sera, 100 L, were dispensed into assay tubes, followed by 100 tL of diluent buffer. Equal volumes of labeled antibody and solid-phase antibody reagents were mixed and 200 pL of the mixture was added to each assay tube. The tubes were incubated at room temperature for 1 h, then 1 mL of wash buffer was added to each tube. The tubes were then centrifuged at 2000 x g for 15 mm and the supernates were carefully decanted.
The washing procedure was repeated and the mouths of the tubes were blotted to remove residual wash buffer.
The pellets were measured luminometrically in a Berth- 
Analytical recoveries.
Recovery experiments were performed by adding known amounts of AFP standard in diluent buffer (final volume, 100 L) to 100 iL of various serum pools, one of which consisted of a badly hemolyzed sample. A dilution experiment was performed in which a pool of high AFP serum was serially diluted with horse serum and the AFP concentration in the solutions assayed as described above. Effect of specific activity. We performed a few assays using a higher specific activity labeled monoclonal antibody (approximately 6 x 106 photons/ng, 2.8 mol of label per mole of antibody). Here, the amount of solid-phase antibody was identical to that used in the other assays but the labeled antibody concentration used was such that the nonspecific binding of the assay was similar to that of the routine assay. This was obtained by using approximately 9 ng per tube.
Data processing.
The results returned by the ici& of clinical serum samples were compared with results of radioimmunoassay of the same specimens. for all assays, were plotted against the mean responses and a linear least squares fit was applied to the data to obtain an expression for the response error relationship (RER). Replicates that differed by 15% or greater were rejected, such samples being reassayed. The RER was applied to the mean dose-response curve obtained from several assays such that a systematic error envelope was generated.
Response errors were transformed to dose errors by dividing the former by the slope of the dose-response curve at several points covering the whole range of the curve. Precision proffles were generated by plotting the dose error vs the dose, thence the coefficient of variation against the dose. These were used to calculate the sensitivity of detection and working range of the assays as described by Ekins (8) .
Results
Standard curves obtained by using the acridiium esterlabeled monoclonal and polyclonal antibodies are shown in Figures 1 and 2 , respectively. Tables 1 and 2 show the results of the recovery and dilution experiments. It can be seen that agreement between the assay results and predicted results is good. Figures 3 and 4 show correlation plots for the monoclonal and polyclonal Ic!s, which both yield acceptable correlation coefficients. Table 3 shows a comparison of the results of the routine monoclonal IC!vIA and the RIA as a function of the gestational age at which the blood sample was taken. These data do not represent normal ranges, because several samples contained high AFP concentrations that may have been symptomatic of fetal abnormality, but they serve to show that the trend of increasing AFP concentrations with gestational age is reflected by both the ICMA and the radioimmunoassay.
Note that the lower cutoff of the latter is 21.2 kilo-mt. units/L and that values below this are not RIA, (---) assays, plotted as coefficient of say sensitivity is governed more by the detectability of the labeled antibody than by its affinity (10). Therefore, under conditions where nonspecific binding is constant, sensitivity should be improved by increasing the specific activity of the label. This is observed in practice, as shown in Figure 6 where increasing the specific activity of the labeled antibody from 0.3 to 2.8 mollmol produced an approximate fivefold increase in sensitivity. In common with other non-isotopic immunoassay techniques, in the icss a label is used that has the advantage of long-term stability. Studies with acridinium ester-labeled antibodies have revealed no detectable deterioration in performance during six months. In addition, the icr provides a means of measuring polypeptides with a sensitivity equal to or greater than that achieved by using 'Ibased techniques.
To date this has proved impossible with the more conventional non-isotopic immunoassay methodologies involving fluorescent or enzyme labels.
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